Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
329.00    0.00 (0.00%)
Bid:
322.00
Ask:
336.00
Spread: 14.00 (4.348%)
Market Cap: £41.75m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Share Buyback

31 Mar 2016 07:20

RNS Number : 6564T
BrainJuicer Group PLC
31 March 2016
 

 

 

 

Press Release

31 March 2016

 

BrainJuicer Group PLC (AIM: BJU)

("BrainJuicer" or "the Company")

 

Share Buyback

 

BrainJuicer, the innovative international market research agency, is pleased to announce its intention to commence, with immediate effect, a share buy-back (the "Buyback") using existing cash resources to make market purchases of up to 1 million of its ordinary shares pursuant to the general authority given to it at the Company's 2015 Annual General Meeting.

 

Following the full year results announcement on Monday 21 March 2016, and the recent weakness in the share price, and in line with the stated commitment to return excess capital to shareholders, the Board has decided to implement the Buyback. Accordingly, any shareholders wishing to participate in the Buyback should contact the Company's broker Canaccord Genuity Limited. The Buyback shall be effected in such manner and on such terms as the directors of the Company may from time to time determine.

 

The maximum price to be paid shall not be more than the higher of: (i) 5% above the average middle market closing price of the Company's shares for the 5 business days immediately preceding the day on which the purchase is made; and (ii) that stipulated by article 5(1) of the Buyback and Stabilisation Regulation.

 

The Buyback will be undertaken until the earlier of all 1 million ordinary shares being repurchased and the Company's 2016 Annual General Meeting on 6 May 2016. Any Shares repurchased will be held in Treasury.

 

Due to the general illiquidity in trading of BrainJuicer's ordinary shares, in order for the Company to buy back ordinary shares, it will be purchasing materially in excess of the limit of 25 per cent. and/or 50 per cent. of average daily volume in the 20 trading days preceding the date of the purchase as is set out in the Code of Market Conduct and, as such, the Company would be deviating from the safe harbour set out in MAR 1 Annex 1 to the Code of Market Conduct. Should a repurchase exceed either the 25 per cent. or 50 per cent. levels, such repurchase is likely to represent a significant proportion of the daily trading volume.

 

John Kearon, Chief Executive Officer of the Company, intends to participate in the Buyback. The Buyback will be conducted conditional upon John's interest in the ordinary shares of the Company, and those deemed to be acting in concert with him, not increasing beyond the percentage of voting rights currently held.

 

The Company will make further announcements in due course following the completion of any purchase of ordinary shares pursuant to the Buyback.

 

The Company confirms it currently has no unpublished price sensitive information.

 

 

For further information, please contact:

BrainJuicer Group PLC

Tel: +44 (0)20 7043 1000

 

John Kearon, Chief Executive Officer

 

James Geddes, Chief Financial Officer

 

Canaccord Genuity Limited (Nomad)

Tel: +44 (0)20 7523 8000

Simon Bridges / Henry Fitzgerald-O'Connor / Emma Gabriel

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
POSJBMFTMBBJMBF
Date   Source Headline
7th Jan 20227:00 amRNSShare Buyback Programme
4th Jan 20222:00 pmRNSDirectorate Change
30th Nov 20214:51 pmRNSDirector Dealings
30th Nov 20217:00 amRNSINTERIM RESULTS
9th Nov 20217:00 amRNSComplaint for Trademark Infringement
29th Oct 20211:24 pmRNSGrant of Options
20th Oct 20217:00 amRNSTrading Update
13th Aug 20215:24 pmRNSAnnual General Meeting
13th Aug 20217:00 amRNSTrading Update for the Annual General Meeting
4th Aug 20216:15 pmRNSUpdate re 2021 AGM
20th Jul 20212:30 pmRNSAnnual Report and Notice of AGM
14th Jul 20217:00 amRNSFinal Results
23rd Jun 202112:30 pmRNSNotice of Results
21st May 20217:00 amRNSExercise of Options and Total Voting Rights
17th May 202112:12 pmRNSDirector/PDMR Shareholding
28th Apr 20211:08 pmRNSDirector/PDMR Shareholding
23rd Apr 202111:16 amRNSCorrection re Directors Dealings
23rd Apr 20219:40 amRNSExercise of Options, Directors Dealings and TVR
21st Apr 20217:00 amRNSTrading Update
30th Mar 20217:00 amRNSChange in Executive Job Titles
15th Feb 202112:42 pmRNSBoard Changes
12th Feb 202111:00 amRNSPrice Monitoring Extension
20th Jan 20217:00 amRNSDirector/PDMR Shareholding
2nd Dec 20204:30 pmRNSGrant of Options
27th Nov 20207:00 amRNSDirector/PDMR Shareholding
17th Nov 20206:27 pmRNSDirector/PDMR Shareholding
17th Nov 20207:00 amRNSInterim Results
14th Oct 20207:00 amRNSTrading Update
12th Oct 20201:40 pmRNSHolding(s) in Company
7th Oct 20202:33 pmRNSHolding(s) in Company
24th Sep 20204:08 pmRNSHolding(s) in Company
4th Aug 20209:39 amRNSDirector/PDMR Shareholding - Replacement
3rd Aug 20205:33 pmRNSDirector/PDMR Shareholding
31st Jul 20206:34 pmRNSResult of AGM
6th Jul 20204:33 pmRNSAnnual Report and Notice of AGM
3rd Jul 202012:22 pmRNSDirector/PDMR Shareholding
2nd Jul 202010:04 amRNSDirector/PDMR Shareholding
30th Jun 20207:00 amRNSFinancial results to 31 March 2020
26th Jun 20202:00 pmRNSExercise of Options and Total Voting Rights
26th Jun 20207:00 amRNSDirectorate Change
26th Jun 20207:00 amRNSDirectorate Change
27th Apr 20207:00 amRNSTrading Update
3rd Apr 20207:00 amRNSChief Financial Officer Resignation
24th Mar 20204:40 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Feb 20207:00 amRNSTrading Update and Planned Share Buyback
23rd Dec 20193:30 pmRNSExercise of Options and Total Voting Rights
7th Nov 20199:29 amRNSDividend Declaration
7th Nov 20197:00 amRNSInterim Results
14th Oct 20197:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.